相关实验视频

Updated: Jul 9, 2025

An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis

Published on: February 8, 2019

托西利祖马布与甲索特雷克萨特在受活性GCA影响的患者队列中:一项临床和超声波比较研究

Silvia Grazzini¹, Edoardo Conticini¹, Paolo Falsetti¹

¹Rheumatology Unit, Department of Medicine, Surgery and Neurosciences, University of Siena, Siena, Italy.

Biologics : targets & therapy

|December 7, 2023

概括

托西利祖马布在巨细胞动脉炎 (GCA) 中快速诱导临床和超声波缓解,与甲状腺素相比. 在接受tocilizumab治疗的GCA患者中,早期止血是安全有效的.

科学领域:

类风湿病学类风湿病学
免疫学免疫学免疫学
内部医学内部医学

背景情况:

巨细胞动脉炎 (GCA) 是一种系统性血管炎,影响大动脉.
有限的对比研究将tocilizumab和甲铁酸与GCA治疗进行比较.
对GCA活动的超声波评估是一个新兴的结果措施.

研究的目的:

为了比较托西利祖马布与甲铁酸盐在实现GCA中的超声波缓解方面的疗效.
评估早期葡萄糖皮质类药物戒断在接受托西利祖马布治疗的GCA患者中的有效性.

主要方法:

对活跃的GCA患者进行前性研究.
纳入标准:临床GCA诊断,活跃疾病和美国基线数据 (光计数和OGUS得分).
患者接受了托西利祖马布或甲铁酸盐,评估时间为3,6个月和12个月.

主要成果:

在大多数患者中,托西利祖马布在6个月内导致了快速的临床和超声波缓解.
所有托西利祖马布患者在12个月内实现了无葡萄糖皮质体缓解.
甲托雷克萨特的反应较慢,在美国1年后出现显著改善;两组都减少了葡萄糖皮质激素剂量,没有出现重大复发.

结论:

托西利祖马布在GCA的临床和超声波缓解方面表现出优越的速度,与甲醇相比.
早期停用葡萄糖皮质类药物是可行的,并且不会增加用tocilizumab治疗的GCA患者的复发风险.

关键词:

这是GCA的GCA.巨细胞动脉炎的发生甲基特雷克萨酸盐的使用方法这就是为什么tocilizumab.超声波学超声波学超声波学血管炎是一种血管炎.

更多相关视频

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...